Last reviewed · How we verify
Cultured Thymus Tissue
Cultured thymus tissue provides thymic factors and hormones that support immune system development and T-cell maturation.
Cultured thymus tissue provides thymic factors and hormones that support immune system development and T-cell maturation. Used for Immunodeficiency disorders, Thymic insufficiency.
At a glance
| Generic name | Cultured Thymus Tissue |
|---|---|
| Also known as | RETHYMIC, allogeneic cultured thymus tissue-agdc, Thymus Tissue Transplant |
| Sponsor | Sumitomo Pharma Switzerland GmbH |
| Drug class | Thymic extract/cultured tissue immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Thymus tissue contains thymic epithelial cells and produces thymic hormones (such as thymosin and thymopoietin) that are essential for T-lymphocyte differentiation and maturation. By providing these factors, the cultured tissue aims to restore or enhance immune function, particularly in conditions characterized by thymic insufficiency or immune deficiency. This approach represents a form of cellular/tissue-based immunotherapy.
Approved indications
- Immunodeficiency disorders
- Thymic insufficiency
Common side effects
Key clinical trials
- Congenital Athymia Patient Registry
- Expanded Access Protocol Thymus Transplantation (PHASE4)
- Thymus Transplantation Safety-Efficacy (NA)
- Serum-Free Thymus Transplantation in DiGeorge Anomaly (PHASE1)
- Thymus Transplantation Dose in DiGeorge #932 (PHASE2)
- Thymus Transplantation in DiGeorge Syndrome #668 (PHASE2)
- Phase I/II Thymus Transplantation With Immunosuppression #950 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cultured Thymus Tissue CI brief — competitive landscape report
- Cultured Thymus Tissue updates RSS · CI watch RSS
- Sumitomo Pharma Switzerland GmbH portfolio CI